STOCK TITAN

Penumbra, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 3, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

ALAMEDA, Calif., Oct. 6, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2022 after market close on Thursday, November 3, 2022 at 4:30 PM Eastern Time. A press release with third quarter 2022 financial results will be issued after market close that day.

Webcast & Conference Call Information
The conference call can be accessed live over the phone by dialing (888) 330-2443 for domestic and international callers (conference id: 4604622), or the webcast can be accessed on the "Events" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.

About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.

Investor Relations

Penumbra, Inc.
510-995-2461
Investors@penumbrainc.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-schedules-third-quarter-2022-earnings-release-and-conference-call-for-november-3-2022-301643172.html

SOURCE Penumbra, Inc.

Penumbra Inc

NYSE:PEN

PEN Rankings

PEN Latest News

PEN Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
US
Alameda

About PEN

penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.